Identification

Name
Terconazole
Accession Number
DB00251  (APRD00659)
Type
Small Molecule
Groups
Approved
Description

Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia]

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Terazol 3Suppository80 mg/1VaginalOrtho Mc Neil Janssen Pharmaceutical1988-06-272016-10-13Us
Terazol 3Cream8 mg/gVaginalJanssen Pharmaceuticals1991-02-21Not applicableUs
Terazol 3Cream8 mg/gVaginalA S Medication Solutions1991-02-212017-06-20Us
Terazol 3Cream8 mg/gVaginalOrtho Mc Neil Janssen Pharmaceutical1991-02-212016-10-13Us
Terazol 3Suppository80 mg/1VaginalJanssen Pharmaceuticals1988-05-24Not applicableUs
Terazol 3 Vaginal Cream 0.8%Cream0.8 %VaginalJanssen Pharmaceuticals1992-12-312007-08-11Canada
Terazol 3 Vaginal Ovules 80mgInsert80 mgVaginalJanssen Pharmaceuticals1991-12-312008-08-08Canada
Terazol 7Cream4 mg/gVaginalJanssen Pharmaceuticals1987-12-31Not applicableUs
Terazol 7Cream4 mg/gVaginalOrtho Mc Neil Pharmaceuticals1988-06-272017-06-30Us
Terazol 7 Vaginal Cream 0.4%Cream4 mgVaginalJanssen Pharmaceuticals1991-12-312016-11-30Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Taro-terconazole CreamCream0.4 %VaginalTaro Pharmaceuticals, Inc.2004-09-21Not applicableCanada
TerconazoleCream4 mg/gVaginalTaro Pharmaceuticals U.S.A., Inc.2005-01-19Not applicableUs
TerconazoleCream4 mg/gVaginalA S Medication Solutions2004-04-012017-06-20Us
TerconazoleCream4 mg/gVaginalA S Medication Solutions2005-01-19Not applicableUs
TerconazoleCream8 mg/gVaginalPhysicians Total Care, Inc.2004-11-18Not applicableUs
TerconazoleCream8 mg/gVaginalActavis Pharma Company2004-04-01Not applicableUs
TerconazoleCream8 mg/gVaginalTaro Pharmaceuticals U.S.A., Inc.2004-04-06Not applicableUs
TerconazoleCream8 mg/gVaginalA S Medication Solutions2004-04-012017-06-20Us
TerconazoleCream4 mg/gVaginalRebel Distributors2005-01-19Not applicableUs
TerconazoleSuppository80 mg/1VaginalTaro Pharmaceuticals U.S.A., Inc.2007-03-09Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Terazol 3 Dual PakTerconazole (0.8 %) + Terconazole (80 mg)Cream; Insert; KitVaginalJanssen Pharmaceuticals1994-12-312014-03-19Canada
Terazol 3 Dual PakTerconazole (0.8 %) + Terconazole (80 mg)Cream; Insert; KitVaginalJanssen Pharmaceuticals1994-12-312014-03-19Canada
International/Other Brands
Terazol / Terazol 3
Categories
UNII
0KJ2VE664U
CAS number
67915-31-5
Weight
Average: 532.462
Monoisotopic: 531.180395297
Chemical Formula
C26H31Cl2N5O3
InChI Key
BLSQLHNBWJLIBQ-OZXSUGGESA-N
InChI
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
IUPAC Name
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine
SMILES
CC(C)N1CCN(CC1)C1=CC=C(OC[[email protected]]2CO[[email protected]@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1

Pharmacology

Indication

For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.

Structured Indications
Pharmacodynamics

Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.

Mechanism of action

Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.

TargetActionsOrganism
ALanosterol 14-alpha demethylase
antagonist
Yeast
Absorption

Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations

Volume of distribution
Not Available
Protein binding

94.9%

Metabolism

Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.

Route of elimination

Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.

Half life

6.9 hours (range 4.0-11.3)

Clearance
Not Available
Toxicity

The oral LD50 values were found to be 1741 and 849 mg/kg for the male and female in rat.

Affected organisms
  • Fungi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of Terconazole can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Terconazole can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terconazole.Approved, Investigational
AmrinoneThe therapeutic efficacy of Terconazole can be increased when used in combination with Amrinone.Approved
AtorvastatinThe risk or severity of myopathy can be increased when Terconazole is combined with Atorvastatin.Approved
AzelnidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Terconazole can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Barnidipine.Approved
BencyclaneThe therapeutic efficacy of Terconazole can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Terconazole can be increased when used in combination with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Terconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Terconazole.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Terconazole can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Terconazole can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Terconazole.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of Terconazole can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Terconazole.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Terconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Terconazole can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Terconazole.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Terconazole.Approved, Investigational
DotarizineThe therapeutic efficacy of Terconazole can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Terconazole can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Terconazole can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Terconazole.Approved
FelodipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Terconazole can be increased when used in combination with Fendiline.Withdrawn
FlunarizineThe therapeutic efficacy of Terconazole can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Terconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of Terconazole can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of Terconazole can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Terconazole can be increased when used in combination with Gallopamil.Investigational
IsradipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Terconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Terconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Terconazole can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Terconazole can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Terconazole.Approved
Magnesium sulfateThe therapeutic efficacy of Terconazole can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Manidipine.Approved, Investigational
MethsuximideThe therapeutic efficacy of Terconazole can be increased when used in combination with Methsuximide.Approved
MibefradilThe therapeutic efficacy of Terconazole can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Terconazole can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Terconazole can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Terconazole can be increased when used in combination with Nitrendipine.Approved, Investigational
OtiloniumThe therapeutic efficacy of Terconazole can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Terconazole.Approved, Vet Approved
PinaveriumThe therapeutic efficacy of Terconazole can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of Terconazole can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Terconazole.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Terconazole.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Terconazole.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Terconazole.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Terconazole.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Terconazole.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terconazole.Approved, Investigational
SeletracetamThe therapeutic efficacy of Terconazole can be increased when used in combination with Seletracetam.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Terconazole.Approved
SucralfateSucralfate can cause a decrease in the absorption of Terconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Terconazole.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Terconazole.Approved, Investigational
TerodilineThe therapeutic efficacy of Terconazole can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Terconazole can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Terconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Terconazole can be increased when used in combination with Tranilast.Approved, Investigational
TrimebutineThe therapeutic efficacy of Terconazole can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Terconazole can be increased when used in combination with Trimethadione.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terconazole.Approved
VerapamilThe therapeutic efficacy of Terconazole can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Terconazole can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Terconazole can be increased when used in combination with WIN 55212-2.Experimental
XylometazolineThe therapeutic efficacy of Terconazole can be increased when used in combination with Xylometazoline.Approved, Investigational
ZiconotideThe therapeutic efficacy of Terconazole can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Terconazole.Approved
ZonisamideThe therapeutic efficacy of Terconazole can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014396
KEGG Drug
D00888
KEGG Compound
C08080
PubChem Compound
441383
PubChem Substance
46505257
ChemSpider
390122
BindingDB
50375318
ChEBI
82980
ChEMBL
CHEMBL1306
Therapeutic Targets Database
DAP000629
PharmGKB
PA164768834
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Terconazole
ATC Codes
G01AG02 — Terconazole
AHFS Codes
  • 84:04.08.08 — Azoles
FDA label
Download (33.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHIV Prevention1
3CompletedTreatmentVaginal Infections1
3RecruitingTreatmentVaginal Infections1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Altana inc
  • Nycomed us inc
  • Taro pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • Perrigo new york inc
Packagers
Dosage forms
FormRouteStrength
CreamVaginal0.4 %
CreamVaginal8 mg/g
SuppositoryVaginal80 mg/1
Cream; insert; kitVaginal
CreamVaginal0.8 %
InsertVaginal80 mg
CreamVaginal4 mg/g
CreamVaginal4 mg
Prices
Unit descriptionCostUnit
Terazol 3 0.8% Cream 20 gm Tube55.99USD tube
Terazol 7 0.4% Cream 45 gm Tube54.0USD tube
Terazol 3 3 80 mg Suppository Box53.99USD box
Terconazole 3 80 mg Suppository Box50.9USD box
Terconazole 0.4% Cream 45 gm Tube42.57USD tube
Terconazole 0.8% Cream 20 gm Tube42.57USD tube
Terazol 3 cream2.64USD g
Zazole 0.8% vaginal cream2.54USD g
Terconazole 0.8% cream2.35USD g
Terazol 7 cream1.17USD g
Terconazole 0.4% cream0.96USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)126.3 °CNot Available
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0116 mg/mLALOGPS
logP4.58ALOGPS
logP5.37ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area64.88 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity153.19 m3·mol-1ChemAxon
Polarizability56.15 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.6657
Caco-2 permeable+0.6081
P-glycoprotein substrateSubstrate0.7064
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.7891
Renal organic cation transporterInhibitor0.5272
CYP450 2C9 substrateNon-substrate0.8484
CYP450 2D6 substrateNon-substrate0.8227
CYP450 3A4 substrateSubstrate0.6986
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8354
Ames testNon AMES toxic0.5825
CarcinogenicityNon-carcinogens0.7686
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6633
hERG inhibition (predictor II)Inhibitor0.603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00o0-3971230000-dd66741ee49b1efec5ef

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Phenoxy compounds / Dichlorobenzenes / Dialkylarylamines / Aniline and substituted anilines / Alkyl aryl ethers / N-alkylpiperazines / Ketals / Aryl chlorides
show 9 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / 1,3-dichlorobenzene / Phenoxy compound / Phenol ether / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Alkyl aryl ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
1-(4-\{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy\}phenyl)-4-isopropylpiperazine (CHEBI:82980)

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
Yes
Actions
Antagonist
General Function
Sterol 14-demethylase activity
Specific Function
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name
ERG11
Uniprot ID
P10613
Uniprot Name
Lanosterol 14-alpha demethylase
Molecular Weight
60674.965 Da
References
  1. Vanden Bossche H, Marichal P: Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. [PubMed:1951574]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  3. Cauwenbergh G, Vanden Bossche H: Terconazole. Pharmacology of a new antimycotic agent. J Reprod Med. 1989 Aug;34(8 Suppl):588-92. [PubMed:2677363]

Drug created on June 13, 2005 07:24 / Updated on February 21, 2018 02:47